THE outcomes from the 31 May meeting of the Drug Utilisation Sub-Committee of the Pharmaceutical Benefits Advisory Committee have been released, looking at utilisation of PBS medicines for the treatment of ADHD, melanoma, fungal infections, spasticity/dystonia and age related macular degeneration.
See pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Jul 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Jul 18
